Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Vaxxel Logo
Vaxxel Growth Score
67
CB Rank
135215
Heat Score
51
Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections
Founded
obfuscation
PrivateSeed Villeurbanne, Rhone-Alpes, France11-50 vaxxel.fr
Pharmaceutical
Overview

Vaxxel
Total Funding
obfuscation
Growth Score
67
Heat Score
51

Total Funding
obfuscation
obfuscation
Seed raised
obfuscation
Growth Score67
-2 pts
in past quarter
Heat Score 51
-7 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Vaxxel

CB Rank
135215
Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections
Founded
obfuscation
PrivateSeed Villeurbanne, Rhone-Alpes, France11-50 vaxxel.fr
Pharmaceutical

Funding Rounds

Seed
OBF
in
obfuscation

Key People

Details

Legal Name Vaxel SAS
Operating Status Active
Company Type For Profit
Founders  Denis Cavert, Manuel Rosa Calatrava
About the Company
Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.
Contact Email contact@vaxxel.fr
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Intranasal Live-Attenuated Vaccine Candidates
Vaxxel develops live-attenuated vaccines administered intranasally to prevent infections caused by pneumoviruses such as RSV and HMPV.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 1
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed
obfuscation
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
3
obfuscation
— Seed

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Bpifrance Logo
Bpifrance
—
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
—
Bpifrance Logo
Bpifrance
—
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
—
Bpifrance Logo
Bpifrance
—
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
—
Bpifrance Logo
Bpifrance
—
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
—
Bpifrance Logo
Bpifrance
—
Seed Round - Vaxxel Logo
Seed Round - Vaxxel
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 2 Contacts 1

Employee Profiles

News
Technology
View Tech Report

IT Spend

$117KThis year, Vaxxel is projected to spend $117K on IT, according to Aberdeen.

Active Website Tech Count

3Vaxxel is actively using 3 technologies for its website, according to BuiltWith. These include Common Crawl, CommonCrawl Top 50m, and  COVID-19.

Total IP

1Vaxxel has 1 registered patent in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Vaxxel's headquarters? Vaxxel is located in Villeurbanne, Rhone-Alpes, France.Who invested in Vaxxel? Vaxxel has 3 investors including Bpifrance and  Angels Santé.When was the last funding round for Vaxxel? Vaxxel closed its last funding round on
obfuscation
from a Seed round.Who are Vaxxel's competitors? Alternatives and possible competitors to Vaxxel may include Pfizer, Sanofi, and  AstraZeneca.How much funding has Vaxxel raised to date? Vaxxel has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(411cf44 1)
|